Rexahn Pharmaceuticals Company Profile (NYSEMKT:RNN)

About Rexahn Pharmaceuticals (NYSEMKT:RNN)

Rexahn Pharmaceuticals logoRexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:RNN
  • CUSIP: N/A
  • Web: https://rexahn.com/cms/
Capitalization:
  • Market Cap: $52.93 million
  • Outstanding Shares: 28,459,000
Average Prices:
  • 50 Day Moving Avg: $2.19
  • 200 Day Moving Avg: $1.72
  • 52 Week Range: $0.13 - $4.74
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.62
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.56 per share
  • Price / Book: 3.32
Profitability:
  • EBIDTA: ($15,840,000.00)
  • Return on Equity: 44.61%
  • Return on Assets: 15.94%
Misc:
  • Average Volume: 234,106 shs.
  • Beta: 0.14
  • Short Ratio: 6.17
 

Frequently Asked Questions for Rexahn Pharmaceuticals (NYSEMKT:RNN)

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "RNN."

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) released its quarterly earnings results on Monday, August, 8th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.02) by $0.01. View Rexahn Pharmaceuticals' Earnings History.

When will Rexahn Pharmaceuticals make its next earnings announcement?

Rexahn Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Rexahn Pharmaceuticals.

Where is Rexahn Pharmaceuticals' stock going? Where will Rexahn Pharmaceuticals' stock price be in 2017?

4 brokers have issued twelve-month price targets for Rexahn Pharmaceuticals' stock. Their forecasts range from $14.00 to $20.00. On average, they expect Rexahn Pharmaceuticals' share price to reach $17.83 in the next twelve months. View Analyst Ratings for Rexahn Pharmaceuticals.

Who are some of Rexahn Pharmaceuticals' key competitors?

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the folowing people:

  • Peter C. Brandt, Independent Chairman of the Board
  • Chang H. Ahn, Chairman Emeritus, Chief Scientist
  • Peter D. Suzdak Ph.D., Chief Executive Officer, Director
  • Tae Heum Jeong, Chief Financial Officer, Secretary
  • Ely Benaim, Chief Medical Officer
  • Charles G. Beever, Independent Director
  • Mark P. Carthy, Independent Director
  • Kwang Soo Cheong Ph.D., Independent Director
  • Richard J. Rodgers, Independent Director

Who owns Rexahn Pharmaceuticals stock?

Rexahn Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Susquehanna International Group LLP (3.57%), Vanguard Group Inc. (3.31%) and Northern Trust Corp (0.19%). View Institutional Ownership Trends for Rexahn Pharmaceuticals.

Who sold Rexahn Pharmaceuticals stock? Who is selling Rexahn Pharmaceuticals stock?

Rexahn Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Northern Trust Corp. View Insider Buying and Selling for Rexahn Pharmaceuticals.

Who bought Rexahn Pharmaceuticals stock? Who is buying Rexahn Pharmaceuticals stock?

Rexahn Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP. View Insider Buying and Selling for Rexahn Pharmaceuticals.

How do I buy Rexahn Pharmaceuticals stock?

Shares of Rexahn Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of Rexahn Pharmaceuticals stock can currently be purchased for approximately $1.86.


MarketBeat Community Rating for Rexahn Pharmaceuticals (NYSEMKT RNN)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Rexahn Pharmaceuticals (NYSEMKT:RNN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.83

Analysts' Ratings History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Show:
DateFirmActionRatingPrice TargetDetails
8/14/2017HC WainwrightReiterated RatingBuy$20.00View Rating Details
8/7/2017Ifs SecuritiesReiterated RatingOutperformView Rating Details
6/9/2017Rodman & RenshawReiterated RatingBuy$19.50View Rating Details
6/1/2017FBR & CoReiterated RatingOutperform$30.00 -> $14.00View Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$1.75View Rating Details
(Data available from 8/20/2015 forward)

Earnings

Earnings History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Earnings by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Earnings History by Quarter for Rexahn Pharmaceuticals (NYSEMKT RNN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.21)N/AView Earnings Details
8/8/2016Q216($0.02)($0.01)ViewN/AView Earnings Details
5/9/2016Q116($0.02)($0.02)ViewN/AView Earnings Details
11/3/2015Q315($0.03)($0.02)ViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.02)ViewN/AView Earnings Details
4/6/2015($0.03)($0.01)ViewN/AView Earnings Details
3/17/2015($0.02)($0.02)ViewN/AView Earnings Details
11/14/2014($0.03)($0.02)ViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.02)ViewN/AView Earnings Details
3/25/2014($0.06)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Current Year EPS Consensus Estimate: $-1.36 EPS
Next Year EPS Consensus Estimate: $-0.71 EPS

Dividends

Dividend History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Insider Trades by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Institutional Ownership by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Insider Trades by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/10/2017Chang Ho AhnDirectorSell250,000$0.70$175,000.00View SEC Filing  
1/12/2015Chang Ho AhnDirectorSell314,656$0.91$286,336.96View SEC Filing  
1/12/2015Tae Heum JeongCFOSell317,272$0.91$288,717.52View SEC Filing  
6/12/2014Chang Ho AhnDirectorSell136,193$0.99$134,831.07View SEC Filing  
9/9/2013Tae Heum JeongCFOSell71,139$0.46$32,723.94View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Latest Headlines for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Source:
DateHeadline
finance.yahoo.com logoRexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans
finance.yahoo.com - August 15 at 6:46 AM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) PT Set at $20.00 by HC Wainwright
www.americanbankingnews.com - August 14 at 1:06 PM
americanbankingnews.com logoIfs Securities Reaffirms "Outperform" Rating for Rexahn Pharmaceuticals, Inc. (RNN)
www.americanbankingnews.com - August 10 at 12:46 PM
finance.yahoo.com logoRexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results
finance.yahoo.com - August 8 at 6:44 AM
finance.yahoo.com logoRexahn posts 2Q profit
finance.yahoo.com - August 8 at 6:44 AM
prnewswire.com logoToday's Research Report Coverage on Biotech Stocks -- Rexahn Pharma, Protalix BioTherapeutics, Navidea ... - PR Newswire (press release)
www.prnewswire.com - July 19 at 7:20 AM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 18 at 9:11 AM
streetinsider.com logoRexahn Pharma (RNN) Granted Allowance for New US Patent Covering the Use of RX-3117 - StreetInsider.com
www.streetinsider.com - July 11 at 4:32 PM
finance.yahoo.com logoRexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117
finance.yahoo.com - July 11 at 7:11 AM
prnewswire.com logoBreakfast Technical Briefing on Biotech Stocks -- Rexahn Pharma, Novavax, and Protalix BioTherapeutics - PR Newswire (press release)
www.prnewswire.com - June 14 at 8:23 AM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Earns "Buy" Rating from Rodman & Renshaw
www.americanbankingnews.com - June 9 at 5:40 PM
finance.yahoo.com logoRexahn Announces $10 Million Registered Direct Offering
finance.yahoo.com - June 7 at 11:38 AM
finance.yahoo.com logoRodman & Renshaw Encouraged on Rexahn Pharmaceuticals, Inc. (RNN) Following ASCO Update
finance.yahoo.com - June 6 at 9:14 PM
streetinsider.com logoRexahn Pharma (RNN) Delivers Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in ... - StreetInsider.com
www.streetinsider.com - June 5 at 8:20 PM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Given a $20.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - June 5 at 2:26 PM
globenewswire.com logoRexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in ... - GlobeNewswire (press release)
globenewswire.com - June 5 at 6:25 AM
nasdaq.com logoRexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial
www.nasdaq.com - June 4 at 9:19 AM
globenewswire.com logoStage 2 of the Study has Begun, Based on Positive Preliminary Efficacy Results from Stage 1 - GlobeNewswire (press release)
www.globenewswire.com - June 4 at 9:19 AM
finance.yahoo.com logoRexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
finance.yahoo.com - June 4 at 9:19 AM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Rating Reiterated by FBR & Co
www.americanbankingnews.com - June 1 at 7:58 PM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) PT Set at $14.00 by FBR & Co
www.americanbankingnews.com - May 27 at 7:46 AM
americanbankingnews.com logoHC Wainwright Reaffirms Buy Rating for Rexahn Pharmaceuticals, Inc. (RNN)
www.americanbankingnews.com - May 22 at 10:54 AM
globenewswire.com logoRexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 ... - GlobeNewswire (press release)
globenewswire.com - May 8 at 6:56 PM
finance.yahoo.com logoRexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
finance.yahoo.com - May 8 at 11:44 AM
streetinsider.com logoRexahn Pharma (RNN) to Trade on Split-Adjusted Basis at Opening; Effects 1-for-10 Reverse Stock Split
www.streetinsider.com - May 6 at 12:50 AM
streetinsider.com logoRexahn Pharma (RNN) to Trade on Split-Adjusted Basis at Opening ... - StreetInsider.com
www.streetinsider.com - May 5 at 7:53 PM
finance.yahoo.com logoRexahn Effects 1-for-10 Reverse Stock Split
finance.yahoo.com - May 5 at 7:49 PM
finance.yahoo.com logoRexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 4 at 7:47 PM
americanbankingnews.com logoRexahn Pharmaceuticals (RNN) Given News Impact Score of 0.10
www.americanbankingnews.com - May 3 at 1:03 AM
americanbankingnews.com logoRexahn Pharmaceuticals (RNN) Earns News Sentiment Score of 0.20
www.americanbankingnews.com - April 28 at 6:54 PM
americanbankingnews.com logoRexahn Pharmaceuticals (RNN) Given News Sentiment Score of 0.31
www.americanbankingnews.com - April 25 at 7:42 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Very Unlikely to Affect Rexahn Pharmaceuticals (RNN) Share Price
www.americanbankingnews.com - April 22 at 3:33 PM
americanbankingnews.com logoSomewhat Negative Media Coverage Unlikely to Affect Rexahn Pharmaceuticals (RNN) Stock Price
www.americanbankingnews.com - April 18 at 7:59 PM
seekingalpha.com logoCould Rexahn Pharmaceuticals Have Something?
seekingalpha.com - April 17 at 6:37 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Very Unlikely to Effect Rexahn Pharmaceuticals (RNN) Stock Price
www.americanbankingnews.com - April 14 at 8:47 PM
finance.yahoo.com logoRexahn Announces 1-for-10 Reverse Stock Split
finance.yahoo.com - April 13 at 9:51 AM
americanbankingnews.com logoChang Ho Ahn Sells 250,000 Shares of Rexahn Pharmaceuticals, Inc. (RNN) Stock
www.americanbankingnews.com - April 12 at 8:09 PM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Given a $2.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 7 at 10:44 PM
streetinsider.com logoRodman & Renshaw Assumes Rexahn Pharmaceuticals Inc. (RNN) at Buy - StreetInsider.com
www.streetinsider.com - April 7 at 7:56 PM
streetinsider.com logoRodman & Renshaw Assumes Rexahn Pharmaceuticals Inc. (RNN) at Buy
www.streetinsider.com - April 7 at 12:20 PM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Coverage Initiated at Rodman & Renshaw
www.americanbankingnews.com - April 6 at 11:55 AM
zacks.com logoRexahn Pharmaceuticals (RNN) Jumps: Stock Moves Up 5.4%
www.zacks.com - March 16 at 8:10 AM
streetinsider.com logoRexahn Pharma (RNN): First Patient Dosed in Phase IIa, Expect Interim Efficacy Readout in 2017 - FBR - StreetInsider.com
www.streetinsider.com - March 1 at 7:51 PM
finance.yahoo.com logoRexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update
finance.yahoo.com - February 27 at 9:30 AM
finance.yahoo.com logoRexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer
finance.yahoo.com - February 23 at 7:43 PM
finance.yahoo.com logoRexahn Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
finance.yahoo.com - February 6 at 7:42 PM
streetinsider.com logoRexahn Pharma (RNN): Niche in Pancreatic Cancer Looks ... - StreetInsider.com
www.streetinsider.com - January 24 at 8:06 AM

Social

This page was last updated on 8/20/2017 by MarketBeat.com Staff